Systemic Lupus Erythematosus
Conditions
Interventions
Case series:add-on or replace dapagliflozin
Sponsors
Dept. Rheumatology, Renji Hospital South Campus
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Willingness of the subject to participate in the study, proven by signing the informed consent; 2) Age at least 18 years old; 3) Systemic lupus erythematosus (SLE), as defined by meeting at least 4 of 11 classification criteria of American College of Rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. The 4 criteria doesn't need to be present at the time of study enrollment; 4) Patients who diagnosed of diabetes mellitus; or glycated albumin(GA)>16% or glycosylated hemoglobin(Hb1c)>6%;or blood glucose > 7.8mmol/L at any time in oral glucose tolerance test(OGTT).
Exclusion criteria
Exclusion criteria: 1) Patients who are unwilling to sign the inform consent; 2) Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) > 2 times upper normal limits; creatinine clearance rate < 45ml/min; 3) Patients who are suffering from infections; 4) Previous exposure of other clinical trails within 3 months before screening; 5) Pregnancy or lactation; 6) patients with mental diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WBC in urine;blood glucose;glycated albumin or glycosylated hemoglobin;C3/C4;unire protein;blood fat;dsDNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI;ESR;CRP;ALT;Cr;blood pressure; | — |
Countries
China
Contacts
Public ContactShuang Ye
Dept. Rheumatology, Renji Hospital South Campus
Outcome results
None listed